Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

Vaccine

Volumn 18, Issue 22, 2000, Pages 2416-2425

  Baldridge, Jory R ^a   Yorgensen, Yvonne ^a   Ward, Jon R ^a   Ulrich, J Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

IgA; MPL; Mucosal immunity

Indexed keywords

ADJUVANT; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; MPL; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; SECRETORY IMMUNOGLOBULIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNITY; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

EID: 0034012994     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00572-1     Document Type: Article

References (39)

1. Tamura S., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immun. 149:(3):1992;981-988.
2. Tamura S., Asanuma H., Tomita T., Komase K., Kawahara K., Danbara H., Hattori N., Watanabe K., Suzuki Y., Nagamine T. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 12:(12):1994;1083-1089.
3. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., Hattori N., Sato T., Suzuki Y., Nagamine T., Aizawa C., Tamura S., Kurata T., Oya A. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 14:(2):1996;113-119.
4. Wilschut J., de Haan A., Geerligs H.J., Huchshorn J.P., van Scharrenburg G.J.M., Palache A.M., Renegar K.B., Small P.A. Liposomes as a mucosal adjuvant system: An intranasal liposomal influenza subunit vaccine and the role of IgA in nasal anti-influenza immunity. J. Liposome Res. 4:(1):1994;301-314.
5. White W.I., Cassatt D.R., Madsen J., Burke S.J., Woods R.M., Wassef N.M., Alving C.R., Koenig S. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine. 13:(12):1995;1111-1122.
6. Eldridge J.H., Gilley R.M., Staas J.K., Moldoveanu Z., Meulbroek J.A., Tice T.R. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr. Top. Microbiol. Immun. 146:1989;59-66.
7. Marx P.A., Compans R.W., Gettie A., Staas J.K., Gilley R.M., Mulligan M.J., Yamschikov G.V., Chen D., Eldridge J.H. Protection against vaginal SIV transmission with microencapsulated vaccine. Science. 260:(5112):1993;1323-1327.
8. Levi R., Aboud-Pirak E., Leclerc C., Lowell G.H., Arnon R. Intransal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine. 13:1995;1353-1359.
9. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immun. 161:(9):1998;4463-4466.
10. Horner A.A., Ronaghy A., Cheng P.M., Nguyen M.D., Cho H.J., Broide D., Raz E. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immun. 190:(1):1998;77-82.
11. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 11:(12):1993;1179-1184.
12. Williams N.A., Hirst T.R., Nashar T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immun. Today. 20:(2):1999;95-101.
13. Chong C., Friberg M., Clements J.D. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 16:(7):1998;732-740.
14. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:(7):1997;2821-2828.
15. Pizza M., Fontana M.R., Giuliani M.M., Domenighini M., Magagnoli C., Giannelli V., Nucci D., Hol W.G.J., Manetti R., Rappuoli R. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 180:1994;2147-2153.
16. Fontana M.R., Manetti R., Giannelli V., Magagnoli C., Marchini A., Olivieri R., Domenighini M., Rappuoli R., Pizza M. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:(6):1995;2356-2360.
17. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Powell M.F., Newman M.J. Vaccine Design: The Subunit and Adjuvant Approach. 1995;495-524 Plenum Press, New York.
18. Neuzil K.M., Johnson J.E., Tang Y.W., Prieels J.P., Slaoui M., Gar N., Graham B.S. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine. 15:(5):1997;525-532.
19. 1. J. Immun. 160:(4):1998;2000-2012.
20. Schirmbeck R., Melber K., Mertens T., Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68:(3):1994;1418-1425.
21. Takayama K., Olsen M., Datta P., Hunter R.L. Adjuvant activity on non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysacchaarides, lipid A and precursors. Vaccine. 9:(4):1991;257-265.
22. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., Alving C.R. Liposomes containing lipid a serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66:(6):1998;2859-2865.
23. Moore A., McCarthy L., Mills K.H.G. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine. 17:1999;2517-2527.
24. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., Vandepapeliere P., Slaoui M., Meheus A. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 16:(7):1998;708-714.
25. Masihi K.N., Lange W., Johnson A.G., Ribi E. Enhancement of chemiluminescence and phagocytic activities by nontoxic and toxic forms of lipid A. J. Biol. Response Mod. 5:(5):1986;462-469.
26. Arend W.P., Massoni R.J. Characteristics of bacterial lipopolysaccharide induction of interleukin 1 synthesis and secretion by human monocytes. Clin. Exp. Immun. 64:(3):1986;656-664.
27. Astiz M.E., Saha D.C., Carpati C.M., Rackow E.C. Induction of endotoxin tolerance with monophosphoryl lipid A in peritonitis: importance of localized therapy. J. Lab. Clin. Med. 123:(1):1994;89-93.
28. Carozzi S., Salit M., Cantaluppi A., Nasini M.G., Barocci S., Cantarella S., Lamperi S. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J. Clin. Microbiol. 27:(8):1989;1748-1753.
29. Gustafson G.L., Rhodes M.J. Effects of tumor necrosis factor and dexamethasone on the regulation of interferon-y induction by monophosphoryl lipid A. J. Immunother. Emphasis Tumor Immun. 15:(2):1994;129-133.
30. Salkowski C.A., Detore G.R., Vogel S.N. Lipopolysaccharide and monophosphoryl lipid a differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 65:(8):1997;3239-3247.
31. MacLean G., Bowen-Yacyshyn M., Samuel J., Meikle A., Stuart G., Nation J., Poppema S., Jerry M., Koganty R., Wong T., Longenecker B. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother. 11:1992;292-305.
32. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 236:(4804):1987;944-947.
33. el Ghazali G.E., Paulie S., Andersson G., Hansson Y., Holmquist G., Sun J.B., Olsson T., Ekre H.P., Troye-Blomberg M. Number of interleukin-4- and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur. J. Immun. 23:(11):1993;2740-2745.
34. Finkelman F.D., Katona I.M., Mosmann T.R., Coffman R.L. IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J. Immun. 140:(4):1988;1022-1027.
35. Snapper C.M., Paul W.E. B cell stimulatory factor-1 (interleukin 4) prepares resting murine B cells to secrete IgG1 upon subsequent stimulation with bacterial lipopolysaccharide. J. Immun. 139:(1):1987;10-17.
36. Husband A.J., Kramer D.R., Bao S., Sutherland R.M., Beagley K.W. Regulation of mucosal IgA responses in vivo: Cytokines and adjuvants. Vet. Immun. Immunopath. 54:(14):1996;179-186.
37. Yamamoto M., Vancott J.L., Okahashi N., Marinaro M., Kiyono H., Fujihashi K., Jackson R.J., Chatfield S.N., Bluethmann H., McGhee J.R. The role of Th1 and Th2 cells for mucosal IgA responses. Ann. NY Acad. Sci. 778:1996;64-71.
38. McGhee J.R., Mestecky J., Elson C.O., Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J. Clin. Immun. 9:(3):1989;175-199.
39. Henricson B.E., Benjamin W.R., Vogel S.N. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect. Immun. 58:(8):1990;2429-2437.